Skip to content
MARKETS / NASDAQ / CMND
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Clearmind Medicine Inc. CMND

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.9M
In brief

What this company does

Clearmind, a clinical stage pharmaceutical company, is engaged in phase I/IIa clinical trials of psychedelic medicines. It has two part-time employees and engages consultants and service providers, including outsourced research and development providers, with all of its employees located in Israel and Canada. Its research programs are focused on the uses of MEAI, a proprietary non-hallucinogenic compound, for the treatment of AUD, weight loss and metabolic disorders and as an alcohol substitute consumer product. MEAI is a synthetic molecule, and it is the active pharmaceutical ingredient of the drug candidate CMND-100. The company was granted approval by the Israeli Ministry of Health and by the FDA to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD. The CM-CMND-001 clinical trial is designed as a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Written from the business description in Clearmind Medicine Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 January 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 6-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -3.7
-2M202020212022202320242025

Total assetsUSD 6.1M
CashUSD 3.9M
Current ratio1.22×

Not available: we don't have the total debt figure for this period.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B······
Operating income CAD B···−0.0−0.0−0.0
EBITDA $B······
Income tax $B0.00.00.00.0··
Net income $B−0.0−0.0−0.0−0.0−0.0·
Free cash flow $B···−0.0−0.0·
EPS, diluted $−30.35−67.80−1703.04−159.11−88.16·
Dividend / sh $······
Payout %······
ROE %······
Shares out B···0.000.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 3 failures in 22 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 54 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code Z4
Fiscal year endsOctober 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image